| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Henry Schein tops Q3 earnings and revenue estimates, boosts 2025 outlook, and expands partnership with KKR amid strong dental a...
https://www.bloomberg.com/news/articles/2025-11-03/kkr-plans-investment-expansion-for-insurance-unit-in-india
$71 million in funding would extend Nanobiotix cash visibility into early 2028Transaction enables Nanobiotix development beyond...
KDP updated its financing package related to the acquisition, now including two new strategic investment agreements totaling $7...
Morgan Stanley analyst Michael Cyprys maintains KKR (NYSE:KKR) with a Overweight and lowers the price target from $170 to $166.